![](/images/graphics-bg.png)
Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
Joint Authors
Delacruz, Wilfred
Setlik, Robert
Hassantoufighi, Arash
Daya, Shyam
Cooper, Susannah
Selby, Dale
Brown, Alexander
Source
Case Reports in Oncological Medicine
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-10-11
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens.
Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics.
We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens.
The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD).
The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response.
This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens.
Both regimens appear effective and have manageable toxicities.
Further clinical trials assessing novel BV combinations are warranted.
American Psychological Association (APA)
Delacruz, Wilfred& Setlik, Robert& Hassantoufighi, Arash& Daya, Shyam& Cooper, Susannah& Selby, Dale…[et al.]. 2016. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
Modern Language Association (MLA)
Delacruz, Wilfred…[et al.]. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
American Medical Association (AMA)
Delacruz, Wilfred& Setlik, Robert& Hassantoufighi, Arash& Daya, Shyam& Cooper, Susannah& Selby, Dale…[et al.]. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1101662